European Journal of Cancer
Volume 36, Issue 16 , Pages 2053-2060 , October 2000

Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma: influence of tumour site, stage, adjuvant chemotherapy and type of mutation

  • R Soong

      Affiliations

    • Department of Surgery, University of Western Australia, Nedlands 6907, Australia
    • Molecular Biology Laboratory, Tan Tock Seng Hospital, Singapore
    • ,
  • B Powell

      Affiliations

    • Department of Surgery, University of Western Australia, Nedlands 6907, Australia
    • ,
  • H Elsaleh

      Affiliations

    • Department of Surgery, University of Western Australia, Nedlands 6907, Australia
    • ,
  • G Gnanasampanthan

      Affiliations

    • Department of Surgery, University of Western Australia, Nedlands 6907, Australia
    • ,
  • D.R Smith

      Affiliations

    • Molecular Biology Laboratory, Tan Tock Seng Hospital, Singapore
    • ,
  • H.S Goh

      Affiliations

    • Molecular Biology Laboratory, Tan Tock Seng Hospital, Singapore
    • ,
  • D Joseph

      Affiliations

    • Department of Medicine, University of Western Australia, Nedlands 6907, Australia
    • ,
  • B Iacopetta

      Affiliations

    • Department of Surgery, University of Western Australia, Nedlands 6907, Australia
    • Corresponding Author InformationCorresponding author. Tel.: +61-8-9346-2085; fax: +61-8-9346-2416

Received 14 March 2000 ,Revised 15 June 2000 ,Accepted 19 July 2000.

References 

  1. World Health Organization. The World Health Report. Geneva, World Health Organization, 1997.
  2. Kirsch DG, Kastan MB. Tumor-suppressor TP53 (implications for tumor development and prognosis). J. Clin. Oncol. 1998;16:3158–3168
  3. Pharoah PD, Day NE, Caldas C. Somatic mutations in the TP53 gene and prognosis in breast cancer (a meta-analysis). Br. J. Cancer. 1999;80:1968–1973
  4. Borresen-Dale AL, Lothe RA, Meling GI, Hainaut P, Rognum TO, Skovlund E. TP53 and long-term prognosis in colorectal cancer (mutations in the L3 zinc-binding domain predict poor survival). Clin. Cancer Res. 1998;4:203–210
  5. Goh HS, Elnatan J, Low CH, Smith DR. TP53 point mutation and survival in colorectal cancer patients (effect of disease dissemination and tumour location). Int. J. Oncol. 1999;15:491–498
  6. Bosari S, Viale G, Roncalli M, et al.  TP53 gene mutations, TP53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am. J. Pathol. 1995;147:790–798
  7. Leahy DT, Salman R, Mulcahy H, Sheahan K, O'Donoghue DP, Parfrey NA. Prognostic significance of TP53 abnormalities in colorectal carcinoma detected by PCR–SSCP and immunohistochemical analysis. J. Pathol. 1996;180:364–370
  8. Soong R, Grieu F, Robbins P, et al.  TP53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin. Cancer Res. 1997;3:1405–1411
  9. Goh HS, Yao J, Smith DR. TP53 point mutation and survival in colorectal cancer patients. Cancer Res. 1995;55:5217–5221
  10. Kressner U, Inganas M, Byding S, et al.  Prognostic value of TP53 genetic changes in colorectal cancer. J. Clin. Oncol. 1999;17:593–599
  11. Powell B, Soong R, Iacopetta B, Seshadri R, Smith DR. Prognostic significance of mutations to different structural and functional regions of the TP53 gene in breast cancer. Clin. Cancer Res. 2000;6:443–451
  12. Soong R, Iacopetta BJ, Harvey JM, et al.  Detection of TP53 gene mutation by rapid PCR–SSCP and its association with poor survival in breast cancer. Int. J. Cancer. 1997;74:642–647
  13. Lim BH, Soong R, Grieu F, Robbins PD, House AK, Iacopetta BJ. TP53 accumulation and mutation are prognostic indicators of poor survival in human gastric carcinoma. Int. J. Cancer. 1996;69:200–204
  14. Elsaleh H, Powell B, Soontrapornchai P, et al.  TP53 gene mutation, microsatellite instability and adjuvant chemotherapy (impact on survival of 388 patients with Dukes’ C colon carcinoma). Oncology. 2000;58:52–59
  15. Elsaleh H, Soontrapornchai P, Grieu F, Joseph D, Iacopetta B. TP53 alterations have no prognostic or predictive significance in Dukes’ C rectal carcinomas. Int. J. Oncol. 1999;15:1239–1243
  16. Soong R, Iacopetta BJ. A rapid and nonisotopic method for the screening and sequencing of TP53 gene mutations in formalin-fixed, paraffin-embedded tumors. Mod. Pathol. 1997;10:252–258
  17. Wilton SD, Lim L, Dye D, Laing N. Bandstab (a PCR-based alternative to cloning PCR products). Biotechniques. 1997;22:642–645
  18. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the TP53 tumor suppressor gene (clues to cancer etiology and molecular pathogenesis). Cancer Res. 1994;54:4855–4878
  19. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a TP53 tumor suppressor–DNA complex (understanding tumorigenic mutations). Science. 1994;265:346–355
  20. Soussi T, Caron de Fromentel C, Mechali M, May P, Kress M. Cloning and characterization of a cDNA from Xenopus laevis coding for a protein homologous to human and murine TP53. Oncogene. 1987;1:71–78
  21. Hainaut P, Hernandez T, Robinson A, et al.  IARC Database of TP53 gene mutations in human tumors and cell lines (updated compilation, revised formats and new visualisation tools (R3 version)). Nucl. Acids Res. 1998;26:205–213
  22. El-Mahdani N, Vaillant JC, Guiget M, et al.  Overexpression of TP53 mRNA in colorectal cancer and its relationship to TP53 gene mutation. Br. J. Cancer. 1997;75:528–536
  23. Hamelin R, Laurent-Puig P, Olschwang S, et al.  Association of TP53 mutations with short survival in colorectal cancer. Gastroenterology. 1994;106:42–48
  24. Iniesta P, Vega FJ, Caldes T, et al.  TP53 exon 7 mutations as a predictor of poor prognosis in patients with colorectal cancer. Cancer Lett. 1998;130:153–160
  25. Jernvall P, Makinen M, Karttunen T, Makela J, Vihko P. Conserved region mutations of the TP53 gene are concentrated in distal colorectal cancers. Int. J. Cancer (Pred. Oncol.). 1997;74:97–101
  26. Lleonart ME, Garcia-Foncillas J, Sanchez-Prieto R, et al.  Microsatellite instability and TP53 mutations in sporadic right and left colon carcinoma. Cancer. 1998;83:889–895
  27. Pauly M, Schmitz M, Kayser I, et al.  Ki-ras oncogene and TP53 tumour suppressor gene mutations in colorectal carcinomas from the European Saar-Luxembourg region are less frequent than predicted by the classic adenoma–carcinoma sequence model. Eur. J. Cancer. 1997;33:2265–2272
  28. Tortola S, Marcuello E, Gonzalez I, et al.  TP53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. J. Clin. Oncol. 1999;17:1375–1381
  29. Watatani M, Yoshida T, Kuroda K, Ieda S, Yasutomi M. Allelic loss of chromosome 17p, mutation of the TP53 gene, and microsatellite instability in right- and left-sided colorectal cancer. Cancer. 1996;77:1688–1693
  30. Delattre O, Olschwang S, Law DJ, et al.  Multiple genetic alterations in distal and proximal colorectal cancer. Lancet. 1989;2:353–356
  31. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 1993;363:558–561
  32. Hardingham JE, Butler WJ, Roder D, et al.  Somatic mutations, acetylator status, and prognosis in colorectal cancer. Gut. 1998;42:669–672
  33. Pricolo VE, Finkelstein SD, Hansen K, Cole BF, Bland KI. Mutated TP53 gene is an independent adverse predictor of survival in colon carcinoma. Arch. Surg. 1997;132:371–375
  34. Benhattar J, Cerottini JP, Saraga E, Metthez G, Givel JC. TP53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int. J. Cancer. 1996;69:190–192

PII: S0959-8049(00)00285-9

European Journal of Cancer
Volume 36, Issue 16 , Pages 2053-2060 , October 2000

Article Tools

* Image Usage & Resolution